Introduction
Two recent groundbreaking reports demonstrated that tumorigenesis in several animal models depends on the heat shock transcription factor Hsf1 (Dai et al., 2007; Min et al., 2007) . For example, hsf1 knockout (KO) dramatically delayed overall development of various tumors and increased survival of p53 knock-in mutant (R172H) mice (Min et al., 2007) . Similarly, Hsf1 deficiency drastically delayed chemical skin carcinogenesis and increased survival (Dai et al., 2007) . Importantly, knockdown of Hsf1 in several cancer cell lines led to significant growth inhibition. The growth dependence of cancer cells on Hsf1 was the basis for a novel concept of 'non-oncogene addiction' of cancer cells (Solimini et al., 2007; Luo et al., 2009) . According to this concept, cancer cells acquire properties that make their survival dependent on proteins that are dispensable for a normal cell, which makes these proteins attractive targets for drug development.
Recently, we developed a cell culture model to investigate effects of Hsf1 on tumor development. In this model, growth of untransformed immortalized human mammary epithelial cells MCF10A was not affected by the short hairpin RNA (shRNA) knockdown of Hsf1 (Meng et al., 2010) . On the other hand, expression of the activated Her2 (ErbB2) oncogene in the Hsf1 knockdown MCF10A cells, instead of transformation, triggered growth arrest and senescence. As a result, these cells could not form tumors in xenografts (Meng et al., 2010) . Accordingly, MCF10A cells expressing Her2 oncogene became 'addicted' to Hsf1. Hsf1 is a transcription factor that affects expression of >5% of human genes, many of which could potentially influence tumor development, for example, multidrug resistance gene 1 (MDR-1), proinflammatory cytokines or metastasis-associated protein (MTA) (Akerfelt et al., 2010) . However, the Hsf1 targets that define the 'addiction' of tumor cells to Hsf1 remain unclear. We hypothesized that the major effect of Hsf1 on tumor development is via regulation of expression of the inducible heat shock protein Hsp72 (Hspa1). Indeed, we have previously demonstrated that Her2 oncogene induces Hsp72 in Hsf1-dependent fashion, and that knockdown of Hsp72 similarly promotes growth arrest and senescence of MCF10A cells expressing Her2 (Meng et al., 2010) . One of the goals of this study was to investigate how Hsp72 regulates Her2-induced senescence of mammary epithelial cells.
In addition to mediating protein folding and degradation (Lindquist and Craig, 1988) , Hsp72 can regulate cell signaling pathways, for example, c-Jun N-terminal kinase, extracellular signal-regulated kinase or nuclear factor-kB, which have important roles in apoptosis, inflammation, diabetes and other physiological responses (Gabai et al., 1997; Jaattela, 1999; Calderwood et al., 2006; Tang et al., 2007; Powers et al., 2008) . There are multiple reports in the literature implicating Hsp72 in tumorigenesis (Jolly and Morimoto, 2000; Mosser and Morimoto, 2004; Ciocca and Calderwood, 2005; Calderwood et al., 2006) . A majority of these reports are correlative studies, demonstrating that in many tumors and cancer cell lines Hsp72 levels are constitutively elevated (Jaattela, 1999; Jolly and Morimoto, 2000; Mosser and Morimoto, 2004; Calderwood et al., 2006) . Moreover, high levels of Hsp72 correlate with metastasis, resistance to anticancer drugs and poor prognosis in many human cancers (Ciocca and Calderwood, 2005) . In addition, there are studies demonstrating that Hsp72 has a critical role in apoptosis survival and proliferation of cancer cell lines in culture. For example, depletion of Hsp72 along with its constitutively expressed housekeeping homolog, Hsc73 (Hspa8), led to apoptosis of certain cancer lines (Powers et al., 2008) . Furthermore, downregulation of Hsp72 alone caused apoptosis or enhanced drug sensitivity (Gabai et al., 2005; Yaglom et al., 2007; Powers et al., 2008) . The latter observation suggests that Hsp72 may be a potential candidate for targeted drug design. In fact, a novel Hsp72 inhibitor has been shown to have tumor suppressor properties (Leu et al., 2009) , however, the drug currently lacks sufficient specificity, and has other targets as well (Leu et al., 2009) .
Previously, we have shown that knockdown of Hsp72 induces senescence in a variety of cancer lines but not in untransformed epithelial cells (Gabai et al., 2009; Meng et al., 2010) . Interestingly, depending on the presence of either phosphoinositide-3-kinase catalytic polypeptide (PIK3CA) or Ras oncogenes depletion of Hsp72 triggered either p53-or mitogen-activated protein kinasedependent senescence signaling pathways (Gabai et al., 2009 ). On the basis of these data, we proposed a novel concept that Hsp72 has a major role in cancer cell evasion of oncogene-induced senescence. According to this concept, oncogene expression in an epithelial cell activates distinct senescence signaling pathways that are kept in check by elevated levels of Hsp72 allowing cell proliferation, and eventually formation of tumors. Conversely, decreasing Hsp72 levels shifts the balance to favor senescence signaling over mitogenic signaling, triggering cell senescence that prevents tumor development.
None of these works, however, addressed genetically effects of Hsp72 in a relevant animal model. Another goal of this investigation was to establish animal breast cancer models, both xenografts and KOs, which are dependent on Hsp72. Further, we aimed to dissect the stage in tumor development that requires Hsp72.
Results

Hsp72 depletion precipitates senescence in MCF10A cells expressing Her2
Previously, we described that Hsf1 knockdown dramatically changes the response of immortalized mammary epithelial cells MCF10A to Her2 oncogene. In these cells, expression of Her2 instead of transformation precipitated senescence (Meng et al., 2010) . We hypothesized that this effect was associated with the failure of Hsf1-mediated Hsp72 induction. This hypothesis was consistent with our observation that Her2 expression in the Hsp72 knockdown MCF10A cells also triggers senescence (Meng et al., 2010) . To further explore this possibility, we investigated whether knockdown of Hsp72 changes the responses of MCF10A cells to expression of Her2 similarly to Hsf1. Accordingly, late passage MCF10A cells were infected with control retrovirus or retrovirus expressing the shRNA against Hsp72 shHsp72 (Meng et al., 2010) and selected with puromycin for 48 h, which resulted in more than 80% downregulation of Hsp72 (Figure 1a ). This treatments did not affect cell viability, and only slightly diminished growth rate (Figure 1b ), indicating that Hsp72 is dispensable for growth of normal cells. Then cells were infected with retrovirus expressing the constitutively active Her2 mutant V664E (neuT). On day 2 post-infection, cells were plated and the cell number was counted every 2 days. Knockdown of Hsp72 slightly decreased the growth of control MCF10A cells ( Figure 1b ). Expression of Her2 also caused a minor reduction of growth rate in control cells (probably because of a slight p21 upregulation, see bellow, Figure 2a ). Importantly, when we expressed Her2 in Hsp72-depleted cells, a dramatic growth inhibition was observed ( Figure 1b ). This slowdown of cell proliferation did not result from apoptosis, since little poly-ADP-ribose polymerase (PARP) cleavage was found under these conditions (Supplementary Figure S1 ). On the other hand, there was a pronounced change in cell morphology indicative of senescence, including enlarged, flattened morphology, extensive vacuolization ( Figure 1c ) and appearance of the senescence-associated b-galactosidase (b-gal) activity (Meng et al., 2010) .
Since Hsp72 was critical for proliferation of Her2expressing MCF10A cells, we further explored if Hsp72 knockdown has effects on cellular transformation. Expression of Her2 in control MCF10A cells led to increased expression of the epithelial-mesenchymal transition marker vimentin, and promoted formation of foci in control MCF10A cells (Figure 1d ), demonstrating that cells underwent neoplastic transformation. In contrast, expression of Her2 in cells with knockdown of Hsp72 led to minimal upregulation of vimentin, and failed to promote foci formation (Figure 1e ), indicating that Hsp72 is critical for Her2-induced transformation in cell culture. Importantly, knockdown of Hsp72 did not reduce Her2 signaling, as judged by activation of the extracellular signal-regulated kinase and Akt pathways. In fact, the extracellular signal-regulated kinase signaling pathway was even over-activated by Her2 in Hsp72depleted cells (Supplementary Figure S2) , similar to what we observed with Ras oncogene expression (Gabai et al., 2009) . Taken together with the observation that expression of Her2 in control cells led to increased Hsp72 levels (Meng et al., 2010) , this provides further support for the 'chaperone addiction' model relating increased Hsp levels to oncogenic transformation.
Hsp72 controls Her2-induced senescence by regulating p21 and surviving To clarify the Her2-induced senescence mechanisms controlled by Hsp72, we assessed the levels of p21 Cip , which is one of the major regulators of senescence in cancer cells (Sherr, 2004; Mooi and Peeper, 2006) . Furthermore, Hsf1 exerts its action on Her2-induced senescence in part through p21 (Meng et al., 2010) . As expected, p21 was mildly upregulated by Her2 expression in MCF10A cells. Similarly, Hsp72-depleted cells showed a minor increase in p21 levels (Figure 2a ). However, there was a strong induction of p21 on expression of Her2 in shHsp72 cells (Figure 2a ). To investigate the importance of p21 in the onset of Her2-induced senescence in cells that lack Hsp72, we used wild-type (WT) and p21 KO MCF10A cells (a kind gift of Dr Park, see reference Altieri, 2003) . In WT MCF10A cells, Hsp72-knockdown caused Her2 expression to induce senescence whereas in p21 KO cells there was little senescence and the cells continue forming foci (Figure 2b and Supplementary Figure S3A ). Therefore, p21 has an important role in Her2-induced senescence and suppression of transformation in Hsp72-depleted cells.
Another component of the Her2-induced senescence regulated by Hsf1 was survivin (Meng et al., 2010) , which affected senescence pathway independent of p21. Therefore, we addressed whether Hsp72 can also regulate the effect of Her2 on survivin. Survivin has a critical role in cell proliferation (Altieri, 2003) , and its expression closely correlates with tumor grade and progression (Altieri 2003 (Altieri , 2008 . In MCF10A cells, expression of Her2 alone had little effect on survivin ( Figure 2c ). Hsp72 knockdown in MCF10A cells caused about 60% downregulation of survivin, which, however, did not significantly affect cell growth, as shown on Figure 1b . However, expression of Her2 in shHsp72 cells led to >90% depletion of survivin. To test for the importance of survivin in Her2-induced senescence, we infected control and shHsp72 MCF10A cells with lentivirus-expressing survivin, and following brief selection infected cells with Her2-expressing virus. Survivin expression rescued the senescence phenotype in Hsp72knockdown cells on Her2 expression, as judged by cell morphology and b-gal staining (Figure 2d and Supplementary Figure S3B ), indicating that suppression of survivin observed in Hsp72 knockdown cells Hsp72 is essential for Her2-induced tumorigenesis L Meng et al significantly contributes to growth inhibition and onset of senescence under these conditions. To understand the relevance of the Hsp72 effects to human cancer, we studied the consequence of Hsp72 knockdown on proliferation of human cell line derived from Her2-positive breast cancer MDA-MB453. In line with data with MCF10A cells, in the MDA-MB453 cells (having WT p53) we observed growth inhibition and induction of p21 on depletion of Hsp72 ( Figure 3a ). Furthermore, there was significant downregulation of survivin in this cell line ( Figure 3a ). Of note, growth inhibition under these conditions was not associated with development of the acidic b-gal activity (data not shown), suggesting that a component of the senescence mechanism responsible for b-gal upregulation is inactivated in this cancer line.
Her2-positive human cancers often lack p53. To understand the relationship between Hsp72-regulated senescence programs, we investigated Her2-positive cancer line SK-BR3, which carries mutant p53. In contrast to MDA-MB453 cells that carry WT p53, Hsp72 depletion did not induce p21 in SK-BR3 cells (Figure 3a ). Nevertheless, depletion of Hsp72 in SK-BR3 led to growth inhibition, which was associated with development of senescent morphology and accumulation of acidic b-gal activity (Figures 3b and c) , pointing to a p53-p21-independent mechanism of senescence. Importantly, knockdown of Hsp72 in SK-BR3 cells led to a strong decrease in survivin levels (Figure 3a) , indicating that effects of Hsp72 on downregulation of survivin were p53 independent.
To test the role of survivin in p53-independent senescence on depletion of Hsp72, we overexpressed survivin in SK-BR3 cells using lentiviral vector, and then knocked down Hsp72, as described above. As judged by suppression of b-gal activity, expression of survivin strongly suppressed senescence in Hsp72depleted SK-BR3 cells (Figure 3b ), indicating that survivin depletion is a critical factor in the p53independent senescence on Hsp72 knockdown.
Thus, Hsp72 exerts its effects on Her2-induced transformation via regulation of p21 and survivin pathways. Taken together, these data indicate that depletion of Hsp72, a downstream target of Hsf1, has similar to Hsf1 knockdown effects on Her2-positive cells, suggesting that Hsp72 is the major contributor to the effects of Hsf1 on Her2-driven transformation. Furthermore, these experiments directly prove the hypothesis that Hsp72 functions to suppress the intrinsic senescence programs activated by Her2 oncogene.
Hsp72-mediated regulation of tumor development in xenograft model
As mentioned in the introduction, so far no animal cancer model has been established to address the Hsp72-dependence of tumor development. Accordingly, we studied the effect of Hsp72 depletion on tumor formation using xenografts in nude mice. Control and Hsp72 knockdown MCF10A cells expressing Her2 were mixed with matrigel and injected subcutaneously in flanks of female nude mice. Her2 appeared to cause very aggressive tumorigenesis, where control Her2-expressing MCF10A cells formed detectable tumors at xenograft injection sites with 100% probability. Tumors appeared by day 3 post-injection and had a very high growth rate (Figure 4a ). In contrast, Her2-expressing Hsp72 knockdown cells did not form tumors for at least 3 weeks. Hsp72 is essential for Her2-induced tumorigenesis L Meng et al In a fraction of animals, tumors became detectable in 3-4 weeks post-injection (Figure 4a ). However, these tumors appear to be selected from cells that escaped Hsp72 knockdown (for example, have lost the Hsp72 shRNA), because Hsp72 levels in these tumors were comparable to that of control cells (Figure 4b ). Therefore, it appears that only cells that escaped the shRNA control could form tumors, indicating the critical role of Hsp72 for tumorigenesis in the xenograft model.
Hsp72-mediated regulation of tumor development in transgenic model
As experiments with the cell culture model indicate that Hsp72 controls the oncogene-induced senescence, a simple prediction was that Hsp72 should regulate early stages of tumorigenesis associated with expression of the oncogenic Her2. Accordingly, depletion of Hsp72 might block early hyperplasia. Xenograft model does not allow dissecting where in the tumorigenic process Hsp72 exerts its activity. Therefore, to address this question, we used the transgenic animal model. Accordingly, we established a mouse model in which Hsp72 KO is combined with expression of Her2. For these experiments, we used mice with both orthologs of human Hsp72, Hsp70a (Hspa1a) and Hsp70b (Hspa1b), deleted (Hunt et al., 2004) and, hereafter termed hsp70 À/À . These animals were bred with mice-expressing Her2/neu (neu-a rodent homolog of Her2) under the control of mouse mammary tumor virus (MMTV) promoter (MMTVneu) (Muller et al., 1996) . Accordingly, we generated WT-MMTVneu þ /À , hsp70 þ /À MMTVneu þ /À , and hsp70 À/ À MMTVneu þ /À mice, and followed tumor development in these animals. As a result of the mixed background, in the experiments with transgenic animals we used littermates WT as controls for the KOs. Immunostaining Hsp72 is essential for Her2-induced tumorigenesis L Meng et al of sections of mammary glands obtained from 3 months old mice indicated that there was a strong induction of Her2/neu transgene in all animal lines compared with control animals, and there was no significant difference in the Her2 expression among the lines (Supplementary Figure S4 ). There was similar tumor incidence between heterozygous hsp70 þ /À MMTVneu þ /À and WT-MMTVneu þ /À mice (median tumor appearance in this strain was 66 weeks), indicating that one copy of the hsp70 genes is sufficient to support mammary tumorigenesis induced by Her2. In contrast, the absence of Hsp72 in the homozygous KO animals almost completely blocked mammary tumor development ( Figure 4c ). Indeed, within >100 weeks no tumors appeared in 10 out of 11 animals, and in one hsp70 À/À MMTVneu þ /À mouse a tumor appeared by 88 weeks of age, which is far later than tumor appearance in control animals. This animal model confirms that Hsp72 is critical for Her2-induced tumor development.
Hsp72 KO blocks hyperplasia and triggers senescence in mammary tissue in mice
To investigate the role of Hsp72 in Her2-induced hyperplasia, whole mounts of mammary glands were taken from 3-month-old virgin mice to evaluate duct branching. By this age Her2 transgene was fully expressed (Supplementary Figure S4 ). Hsp70 KO itself did not affect duct or alveoli morphology (Figure 4c ). Expression of Her2 in WT-MMTVneu þ /À mammary gland strongly enhanced the density of ducts and led to more extensive alveoli branching, as reported previously (Muller et al., 1996) . Importantly, expression of Her2 in the hsp70 À/À background (hsp70 À/À MMTVneu þ /À ) led to dramatic reduction in duct density, as compared with control or hsp70 À/À animals, and completely prevented alveoli branching (Figures 5a and b) . Histological examination by hematoxylin-eosin staining also detected extensive alveoli branching and hyperplasia in WT-MMTVneu þ /À , but not in hsp70 À/À MMTVneu þ /À mice (Figure 5c ). Immunostaining of tissue sections with Ki-67 antibody confirmed extensive cell proliferation in WT-MMTVneu þ /À animals, and lack of such proliferation hsp70 À/À MMTVneu þ /À mice (Figure 5c ). Therefore, Hsp70 KO prevented Her2-induced tissue hyperplasia. In other words, effects of Hsp70 were detected at very early stages, almost 10 months before pulpable tumors appeared.
To address whether Hsp72 KO suppresses Her2dependent tumorigenesis in vivo via precipitating senescence, we performed b-gal staining of mammary glands from 3-month-old mice. There was almost no b-gal staining in control, WT MMTVneu þ /À and hsp70 À/À animals. In contrast, extensive b-gal staining of ducts ( Figure 6a ) was seen when expression of Her2 was combined with Hsp70 KO (hsp70 À/À MMTVneu þ /À ). Therefore in an hsp70 À/À background, Her2/neu oncogene, instead of epithelial transformation, triggers senescence and suppresses alveoli branching. In other words, Hsp72 appears to become critical for hyperplasia on expression of Her2 because it allows epithelial cells to escape growth arrest and senescence controls.
To evaluate whether Hsp72 regulates Her2 effects on p21 and survivin in mammary tissue in vivo, we assessed levels of these proteins in mice by immunohistochemistry. Indeed, we observed strong accumulation of p21 in mammary glands from hsp70 À/À MMTVneu þ /À mouse as compared with tissue from WT-MMTVneu þ /À animals (Figure 6b ). Furthermore, we observed a strong decrease in survivin levels in hsp70 À/À MMTVneu þ /À mouse mammary glands compared with mammary tissue from WT-MMTVneu þ /À animals (Figure 6c) . Therefore, expression of Her2 in cells lacking Hsp72 leads to upregulation of p21 and downregulation of survivin both in vitro and in vivo.
Discussion
This work, which is built on our previous publication on the role of Hsf1 in Her2-induced tumorigenesis, had two goals: first to investigate whether induction Hsp72 is the major contributor to the effects of Hsf1, and second to develop animal models that allow investigating the role of Hsp72 in tumor development. The involvement of Hsp72 in Hsf1-mediated effects on tumorigenesis was hinted by previous observations that (a) Hsp72 is induced by Her2 in Hsf1-dependent manner, and (b) similar to Hsf1 knockdown, expression of Her2 in Hsp72 knockdown precipitates senescence of MCF10A cells instead of promoting transformation (Meng et al., 2010) . Here, we confirmed these observations, and demonstrated that other effects of Hsp72 knockdown on Her2-mediated transformation also recapitulate effects of Hsf1 depletion. In fact, we observed that in the shHsp72 cells Her2 expression blocks proliferation and suppresses EMT, as judged by suppression of foci formation and reduced expression of vimentin (Figures 1d and e) .
Importantly, as with Hsf1 depletion, expression of Her2 in Hsp72 knockdown cells upregulated p21 and downregulated survivin. Both of these effects were found to be involved in Her2-mediated senescence. Indeed, we observed partial suppression of senescence by either KO of p21 or expression of recombinant survivin (Figures 2b and d ). It appears that p21 and survivin represent parallel and independent pathways of senescence controlled by Hsp72. This is evident from the experiments with human Her2-positive cancer cell lines. Indeed, in MDA-MB-453 cells that carry normal p53 depletion of Hsp72 both upregulated p21 and downregulated survivin. These effects were associated with growth inhibition (although b-gal activity was not upregulated, probably because of an additional defect in this pathway). In contrast, in Her2-positive SK-BR-3 cell line, which carry mutant p53, depletion of Hsp72 did not cause upregulation of p21, but still triggered downregulation of survivin, indicating that these pathways are independent, and that survivin regulation is not associated with functional p53. Furthermore, expression of survivin in this cell line was sufficient to almost completely reverse Hsp72 depletion-mediated senescence (Figure 3c ). On the other hand, expression of Hsp72 is essential for Her2-induced tumorigenesis L Meng et al survivin only partially reversed Hsp72 depletion-mediated senescence in MCF10A cells, which have functional p21 pathway, suggesting a significant contribution of p21 in this system (Figure 2 ).
Altogether these experiments with several cell culture models indicated that effects of Hsp72 on Her2-induced transformation are very similar to effects of Hsf1. This finding strongly suggest that Hsp72 in the major factor, which mediates effects of Hsf1 on tumorigenesis. This is an important advance since as mentioned in Introduction almost 5% of human genes are regulated by Hsf1 either directly or indirectly, and identifying the downstream target critical for cancer development is important. On the other hand, while claiming that Hsp72 downregulation is sufficient for effects of Hsf1 knockdown, we realize that it may not be essential, because Hsp27 and possibly other downstream targets could have a role in this regulation as well. In fact, Her2 similarly precipitates senescence in Hsp27-depleted cells. Furthermore, overexpression of Hsp72 is unable to suppress effects of Hsf1 depletion (unpublished data). Nevertheless, strong similarity of effects of Hsp72 knockdown to effects of Hsf1 knockdown indicates that Hsp72 is the important contributor to these effects.
Another goal of this study was to develop animal models to investigate effects of Hsp72 on tumor development. In fact, so far all studies that experimentally addressed the critical role of Hsp72 in tumorigenesis were either done with cell culture or were correlative using biopsies. An exception was recent publication with a novel compound that inhibits Hsp72, which was tested with tumor xenografts (Leu et al., 2009) . However, these data should be taken cautiously because of the obvious question of specificity of the Here, we first demonstrated that shHsp72 MCF10A cells that express Her2 cannot form tumor xenografts in contrast to control Her2-expressing MCF10A cells (Figure 4a ). Although tumors appeared from shHsp72 cells with almost 3 weeks delay, these tumors only support the notion that Hsp72 is essential for Her2-induced tumor formation, because in all of them the shRNA control of Hsp72 expression was lost. Further we addressed at what stage of tumor development Hsp72 exerts its activity. Cell culture experiments suggested that Hsp72 should act early in tumor development when the process of the oncogeneinduced senescence may take place. Accordingly, we expected that Hsp72 KO could suppress Her2-induced hyperplasia of mammary tissue. This kind of analyses is not possible with the xenograft models, and we developed the transgenic model. With this model we observed an extremely strong effect of Hsp72 KO. In fact, there was almost complete prevention of Her2induced mammary tumors in Hsp72 KO animals. As predicted, this effect was associated with suppression of hyperplasia and cell proliferation, as judged by histology and Ki-67 immunostaining ( Figure 5 ). Very importantly, we observed strong b-gal staining indicative of extensive senescence in mammary ducts from Her2expressing Hsp72 KO animals (Figure 6a ). Senescence was so strong that it led not only to suppression of hyperplasia, but also to suppression of normal alveolar branching. These effects were specifically associated with Her2 oncogene, because neither senescence nor suppression of alveolar branching was seen in Hsp72 KO animals that do not express Her2 (Figures 5a and  b ). It should be noted that these effects were seen in young mice, at least several months before tumors appeared. Another important note is that in the transgenic model, we observed both upregulation of p21 and downregulation of survivin in Her2-expressing Hsp72 KO animals specifically (Figures 6b and c) , which recapitulates effects seen in cell culture.
Recently there was a publication that Hsp72 KO does not prevent, but rather promotes carcinogen-induced colon cancer (Tao et al., 2009) . Cancer caused by this carcinogen requires chronic inflammatory response. The investigators argued that Hsp72 KO promotes inflammation and thus facilitates cancer development. This may be the main difference with Her2-induced cancer, which does not require chronic inflammation. The other difference could be in tissue type, since in this work colon cancer was studied, while we study breast cancer.
We conclude that Hsp72 could potentially be an anticancer drug target similar to Hsf1. Furthermore, animal models developed in this work demonstrating full dependence of Her2-induced tumor development on Hsp72 could be used for drug testing.
Materials and methods
Animals
Animal maintenance and experiments were conducted in compliance with IACUC guidelines. MMTVneu þ / þ mice (FVB/N, Jackson's Lab, Bar Harbor, ME, USA) were crossed with WT mice or hsp70 À/À mice (C57/129) to generate WT-MMTVneu þ /À , hsp70 þ /À MMTVneu þ /À and hsp70 À/À MMTVneu þ /À mice. Mice were killed at 3 months of age to study mammary gland hyperplasia or were kept to monitor tumor development.
Cell cultures and reagents MCF10A cells were cultured in Dulbecco's modified Eagle's medium/F12 medium supplemented with 5% horse serum, 20 ng/ml epidermal growth factor, 0.5 mg/ml hydrocortisone, 10 mg/ml human insulin and 100 ng/ml cholera toxin. HEK293T cells were from ATCC (Manassas, VA, USA) and 
Retroviral vectors and infection
RNA interference-Ready pSIREN-RetroQ vector from BD Biosciences (Franklin Lakes, NJ, USA) retroviral delivery system was used for knockdown of Hsp72. The sequence of human Hsp72 gene was selected as reported before (Zaarur et al., 2006) . Her2 and control (pBABE) retroviral vectors were a kind gift of C Spangenberg (Trost et al., 2005) . This version of Her2 carries the activating V664E mutation (NeuT). Retroviruses were produced as reported before (Yaglom et al., 2007; Gabai et al., 2009) . Briefly, HEK293T cells were co-transfected with plasmids expressing retroviral proteins Gag-Pol, VSV-G pseudotype, and enhanced green fluorescent protein or our constructs using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). At 48 h after transfection, supernatants containing the retroviral particles were collected and frozen at -70 1C until use. MCF10A cells were infected with diluted supernatant in the presence of 10 mg/ml Polybrene overnight, and were selected with puromycin (0.75 mg/ml) 48 h after infection. Retroviral vectors expressing enhanced green fluorescent protein was used as infection efficiency indicator: usually B90% of cells were fluorescent 2 days after infection.
Immunoblot analysis
Cells were washed twice with phosphate-buffered saline and lysed in lysis buffer (40 mM HEPES [pH 7.5], 50 mM KCl, 1% Triton X-100, 1 mM Na3VO4, 50 mM glycerophosphate, 50 mM NaF, 5 mM EDTA, 5 mM ethyleneglycol tetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, and 5 mg/ml each leupeptin, pepstatin A, aprotinin). Protein concentration of the lysates was measured with the Bio-Rad (Hercules, CA, USA) protein assay reagent, after which they were diluted with lysis buffer to achieve equal protein concentrations. Antibodies used for this study were listed as follow: anti-Hsp72 from Stressgen (San Diego, CA, USA); anti-p21 and anti-PARP from BD PharMingen (San Diego, CA, USA); anti-vimentin from LabVision (Thermo Scientific, Fremont, CA, USA); anti-survivin from Santa Cruz (Santa Cruz, CA, USA); and anti-b-actin from Sigma (St Louis, MO, USA).
Cell growth and foci formation
Cell growth curve was performed by seeding 5000 cells per well in 12-well plate and cell number was monitored every 2 days. To study foci formation, cells were seeded at 3 Â 10 5 per well in six-well plate and were let grow for 2 days until foci can be observed under microscope. Then cells were washed twice with phosphate-buffered saline, fixed with 2% formaldehyde/0.2% glutaraldehyde in phosphate-buffered saline for 10 min and stained with hematoxylin.
Xenografts
For establishing tumor xenografts, cells were trypsinized, mixed at 1:1 ratio with matrigel, and 0.25 million cells of each culture were injected subcutaneously into 6-week-old female NCR nude mice (Taconic, Hudson, NY, USA). Tumor growth was monitored twice a week using caliper.
b-gal assay b-gal assay was carried out using X-gal (pH 6.0) as described previously (Yaglom et al., 2007; Gabai et al., 2009) . Cells were plated at a low density and fixed with 2% formaldehyde and 0.2% glutaraldehyde. The b-gal activity was determined by incubation with 1 mg/ml of solution of X-gal (5-bromo-4chloro-3-indolyl b-D-galactopyranoside) in 40 mM sodium citrate, 5 mM K 3 FeCN 6 , 5 mM K 4 FeCN 6 , 150 mM NaCl, 2 mM MgCl 2 diluted in phosphate-buffered saline (pH 6.0). The number of stained cells was counted under microscope from five different fields and the proportion of stained cells was calculated. The results were expressed as mean value ± s.d. on three independent experiments. Mammary gland whole mounts were fixed in formalin overnight at 4 1C and were stained with the same b-gal activity assay buffer mentioned above.
Immunohistochemistry
Mammary tissues from 3-month-old virgin mice were fixed in formalin overnight and were processed into paraffin sections (5 mm in thickness). Immunohistochemical staining was performed using the standard ABC method (Vector Laboratory, Burlingame, CA, USA).
